NEW YORK, Dec. 22, 2005 (PRIMEZONE) -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(r) (EIO(r)) on Dallas, Texas-based HemoBioTech, Inc. (OTCBB:HMBT). The full 36-page report can be found at www.crystalra.com, or on HemoBioTech's web site, www.hemobiotech.com.
HemoBioTech, Inc. is a biopharmaceutical company developing innovative blood substitute technology exclusively licensed from Texas Tech University Health Services Center ("Texas Tech"). The Company's core product, HemoTech(tm), is an oxygen-carrying, bovine hemoglobin-based (Hb) solution believed to perform in a manner similar to red blood cells, as well as provide erythropoietic (inducing red blood cell production) and anti-inflammatory activity.
HemoTech(tm) was developed on the premise that free hemoglobin-based blood substitutes can no longer be considered mere "transport vehicles" for oxygen, carbon dioxide, and nutrients. Instead, they should possess pharmacological properties that can reduce the intrinsic toxic effects of hemoglobin and help eliminate abnormal reactions associated with blood pressure reduction and the lowering of vital signs due to blood loss during hemorrhage.
Other efforts to develop blood substitutes have focused not on replacements for whole blood but rather on attempts to duplicate its oxygen-carrying capacity. These development efforts are either hemoglobin-based products derived from discarded human or bovine blood, or composed of artificially produced perfluorochemicals (PCFs). Building on over 35 years of persistent research efforts within the blood substitute industry, HemoBioTech's blood substitute technology, HemoTech(tm), could become a non-toxic, anti-inflammatory, and vasodilatory blood substitute with erythropoietic activity.
HemoBioTech is listed on the OTC Bulletin Board (OTC) under the symbol HMBT.OB.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality fee-based research to small and mid-cap companies. The Company's unique and novel product, the Executive Informational Overview(r) (EIO(r)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(r) presents a crystal-clear, detailed report on a company (whether public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(r) details a company's product/technology/service offerings, market size(s), key intellectual property (IP), leadership, growth strategy, competition, risks, audited financial statements, key events and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by HemoBioTech in cash of $25,000 and 50,000 warrants. Please see back of report for complete Company disclosures.
Forward-Looking Safe Harbor Statement
To the extent that this release discusses any expectations concerning future plans, financial results or performance, such statements are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and are subject to substantial risks and uncertainties. Actual results could differ materially from those anticipated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and reflect only management's belief and expectations based upon presently available information. These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates, LLC assumes no obligation to update any of the forward-looking statements in this release.